METTL3 was found highly expressed in hepatocellular cancer (HCC), whose overexpression elicited HCC growth and lung metastasis via modulating level of SOCS2 in a YTHDF2‐dependent manner.10 Furthermore, METTL14 displayed higher methyltransferase activity than METTL3 in vitro.6, 7 As a consequence, although the positive correlation with favorable clinical indications and prognosis implicated both METTL3/METTL14's tumor suppressive role in GC, METTL14, instead of METTL3, was selected as the representative writer for in vitro verifications. The gene discussed is YTHDF2; the disease is hepatocellular carcinoma.